Metastasectomy (n = 40)	SABR (n = 60)	p Value
Rectal cancer—neoadjuvant RT	5 (26%)	19 (58%)	0.09
Rectal cancer—neoadjuvant CRT	12 (63%)	11 (33%)
Colon cancer—neoadjuvant chemotherapy	1 (5%)	1 (4%)	0.39
Colon cancer—adjuvant chemotherapy	9 (43%)	16 (59%)	0.26
pT1 or pT2	6 (15%)	14 (23%)	0.58
pT3 or pT4	32 (80%)	42 (70%)
pN0	17 (43%)	30 (48%)	0.90
pN1	15 (38%)	18 (30%)
pN2	7 (18%)	10 (17%)
Adenocarcinoma	38 (95%)	59 (82%)	0.89
Mucinous adenocarcinoma	2 (5%)	3 (5%)
Well to moderately differentiated	34 (85%)	38 (63%)	0.78
Poorly or undifferentiated	2 (5%)	3 (5%)
KRAS status unkown	28 (70%)	55 (89%)	0.06
KRASwt	1 (2%)	1 (2%)
KRASmt	11 (28%)	6 (10%)
MSI status unkown	31 (78%)	51 (85%)	0.34
MSS	9 (22%)	8 (13%)
MSI	0	1 (2%)
Data are n (%). MSI = microsatellite instability. MSS = microsatellite stable. KRAS = Kirsten rat sarcoma virus. wt = wild-type. mt = mutation.